Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALM-1 Phase 3 study of BLU-5937 in adults with refractory or unexplained chronic cough
2022-000223-20Phase 3Active
- Sponsor
- BELLUS Health Inc.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of camlipixant in refractory chronic cough (RCC), chronic idiopathic cough (CIC) and chronic cough (3 arms), sponsored by BELLUS Health Inc. Primary endpoint: 24-hour cough frequency at Week 12. Started Oct 2022; status: active.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)chronic cough
Beyond the preview
Go deeper on 2022-000223-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000223-20.